Identification
Namemethyl (1R,2S)-2-(hydroxycarbamoyl)-1-{4-[(2-methylquinolin-4-yl)methoxy]benzyl}cyclopropanecarboxylate
Accession NumberDB07147
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 420.4578
Monoisotopic: 420.168521888
Chemical FormulaC24H24N2O5
InChI KeyHJWMYFBKJRVWJY-YKSBVNFPSA-N
InChI
InChI=1S/C24H24N2O5/c1-15-11-17(19-5-3-4-6-21(19)25-15)14-31-18-9-7-16(8-10-18)12-24(23(28)30-2)13-20(24)22(27)26-29/h3-11,20,29H,12-14H2,1-2H3,(H,26,27)/t20-,24+/m1/s1
IUPAC Name
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-({4-[(2-methylquinolin-4-yl)methoxy]phenyl}methyl)cyclopropane-1-carboxylate
SMILES
[H][C@@]1(C[C@]1(CC1=CC=C(OCC2=CC(C)=NC3=C2C=CC=C3)C=C1)C(=O)OC)C(=O)NO
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Disintegrin and metalloproteinase domain-containing protein 17ProteinunknownNot AvailableHumanP78536 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0023 mg/mLALOGPS
logP3.81ALOGPS
logP3.11ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)8.86ChemAxon
pKa (Strongest Basic)5.02ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area97.75 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity113.42 m3·mol-1ChemAxon
Polarizability44.95 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7354
Blood Brain Barrier+0.6867
Caco-2 permeable-0.6604
P-glycoprotein substrateSubstrate0.6224
P-glycoprotein inhibitor INon-inhibitor0.8375
P-glycoprotein inhibitor IINon-inhibitor0.7036
Renal organic cation transporterNon-inhibitor0.8911
CYP450 2C9 substrateNon-substrate0.8567
CYP450 2D6 substrateNon-substrate0.8119
CYP450 3A4 substrateSubstrate0.6691
CYP450 1A2 substrateNon-inhibitor0.5921
CYP450 2C9 inhibitorNon-inhibitor0.5632
CYP450 2D6 inhibitorNon-inhibitor0.8399
CYP450 2C19 inhibitorNon-inhibitor0.6476
CYP450 3A4 inhibitorNon-inhibitor0.5487
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6316
Ames testAMES toxic0.528
CarcinogenicityNon-carcinogens0.8765
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7595 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9968
hERG inhibition (predictor II)Non-inhibitor0.6053
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as quinolines and derivatives. These are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassQuinolines and derivatives
Direct ParentQuinolines and derivatives
Alternative ParentsPhenoxy compounds / Phenol ethers / Alkyl aryl ethers / Fatty acid esters / Methylpyridines / Cyclopropanecarboxylic acids and derivatives / Heteroaromatic compounds / Methyl esters / Hydroxamic acids / Azacyclic compounds
SubstituentsQuinoline / Phenoxy compound / Phenol ether / Alkyl aryl ether / Methylpyridine / Fatty acid ester / Monocyclic benzene moiety / Cyclopropanecarboxylic acid or derivatives / Fatty acyl / Benzenoid
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, ...
Gene Name:
ADAM17
Uniprot ID:
P78536
Molecular Weight:
93020.165 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on September 15, 2010 15:19 / Updated on June 11, 2017 21:05